Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 380

1.

Degeneration of injured axons and dendrites requires restraint of a protective JNK signaling pathway by the transmembrane protein Raw.

Hao Y, Waller TJ, Nye DM, Li J, Zhang Y, Hume RI, Rolls MM, Collins CA.

J Neurosci. 2019 Sep 6. pii: 0016-19. doi: 10.1523/JNEUROSCI.0016-19.2019. [Epub ahead of print]

PMID:
31492772
2.

Tumour cell invasiveness and response to chemotherapeutics in adipocyte invested 3D engineered anisotropic collagen scaffolds.

Hume RD, Pensa S, Brown EJ, Kreuzaler PA, Hitchcock J, Husmann A, Campbell JJ, Lloyd-Thomas AO, Cameron RE, Watson CJ.

Sci Rep. 2018 Aug 23;8(1):12658. doi: 10.1038/s41598-018-30107-3.

3.

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.

Kernan NA, Richardson PG, Smith AR, Triplett BM, Antin JH, Lehmann L, Messinger Y, Liang W, Hume R, Tappe W, Soiffer RJ, Grupp SA.

Pediatr Blood Cancer. 2018 Oct;65(10):e27269. doi: 10.1002/pbc.27269. Epub 2018 Jun 6.

PMID:
29873895
4.

Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, Lehmann L, Shore T, Ho VT, Bunin N, Iacobelli M, Liang W, Hume R, Tappe W, Soiffer R, Richardson P.

Br J Haematol. 2018 Jun;181(6):816-827. doi: 10.1111/bjh.15267. Epub 2018 May 16.

5.

An Engineered Human Adipose/Collagen Model for In Vitro Breast Cancer Cell Migration Studies.

Hume RD, Berry L, Reichelt S, D'Angelo M, Gomm J, Cameron RE, Watson CJ.

Tissue Eng Part A. 2018 Sep;24(17-18):1309-1319. doi: 10.1089/ten.TEA.2017.0509. Epub 2018 Jul 3.

PMID:
29652604
6.

Restraint of presynaptic protein levels by Wnd/DLK signaling mediates synaptic defects associated with the kinesin-3 motor Unc-104.

Li J, Zhang YV, Asghari Adib E, Stanchev DT, Xiong X, Klinedinst S, Soppina P, Jahn TR, Hume RI, Rasse TM, Collins CA.

Elife. 2017 Sep 19;6. pii: e24271. doi: 10.7554/eLife.24271.

7.

Supplemental Iodide for Preterm Infants and Developmental Outcomes at 2 Years: An RCT.

Williams FLR, Ogston S, Hume R, Watson J, Stanbury K, Willatts P, Boelen A, Juszczak E, Brocklehurst P; I2S2 Team.

Pediatrics. 2017 May;139(5). pii: e20163703. doi: 10.1542/peds.2016-3703. Epub 2017 Apr 14.

8.

Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.

Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, Lehmann L, Miloslavsky M, Hume R, Hannah AL, Nejadnik B, Soiffer RJ.

Br J Haematol. 2017 Jul;178(1):112-118. doi: 10.1111/bjh.14727. Epub 2017 Apr 26.

9.

Human rhinovirus-induced inflammatory responses are inhibited by phosphatidylserine containing liposomes.

Stokes CA, Kaur R, Edwards MR, Mondhe M, Robinson D, Prestwich EC, Hume RD, Marshall CA, Perrie Y, O'Donnell VB, Harwood JL, Sabroe I, Parker LC.

Mucosal Immunol. 2017 May;10(3):829. doi: 10.1038/mi.2017.40. No abstract available.

10.

Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.

Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, Lehmann L, Shore T, Iacobelli M, Miloslavsky M, Hume R, Hannah AL, Nejadnik B, Soiffer RJ; Defibrotide Study Group.

Biol Blood Marrow Transplant. 2017 Jun;23(6):997-1004. doi: 10.1016/j.bbmt.2017.03.008. Epub 2017 Mar 8.

11.

Development of three-dimensional collagen scaffolds with controlled architecture for cell migration studies using breast cancer cell lines.

Campbell JJ, Husmann A, Hume RD, Watson CJ, Cameron RE.

Biomaterials. 2017 Jan;114:34-43. doi: 10.1016/j.biomaterials.2016.10.048. Epub 2016 Nov 1.

12.

Concomitant differentiation of a population of mouse embryonic stem cells into neuron-like cells and schwann cell-like cells in a slow-flow microfluidic device.

Ramamurthy P, White JB, Yull Park J, Hume RI, Ebisu F, Mendez F, Takayama S, Barald KF.

Dev Dyn. 2017 Jan;246(1):7-27. doi: 10.1002/dvdy.24466. Epub 2016 Nov 17.

13.

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program.

Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, Iacobelli M, Niederwieser D, Olavarría E, Suarez F, Ruutu T, Verdonck L, Hume R, Nejadnik B, Lai C, Finetto G, Richardson P.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1874-1882. doi: 10.1016/j.bbmt.2016.07.001. Epub 2016 Jul 7.

14.

Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.

Strouse C, Richardson P, Prentice G, Korman S, Hume R, Nejadnik B, Horowitz MM, Saber W.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1306-1312. doi: 10.1016/j.bbmt.2016.04.011. Epub 2016 Apr 19.

15.

Telemedicine and facility design.

Hume R, Looney J.

Health Facil Manage. 2016 Feb;29(2):30-3. No abstract available.

PMID:
27017802
16.

Human rhinovirus-induced inflammatory responses are inhibited by phosphatidylserine containing liposomes.

Stokes CA, Kaur R, Edwards MR, Mondhe M, Robinson D, Prestwich EC, Hume RD, Marshall CA, Perrie Y, O'Donnell VB, Harwood JL, Sabroe I, Parker LC.

Mucosal Immunol. 2016 Sep;9(5):1303-16. doi: 10.1038/mi.2015.137. Epub 2016 Feb 24.

17.

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.

Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL, Steinbach G, Krishnan A, Nemecek ER, Giralt S, Rodriguez T, Duerst R, Doyle J, Antin JH, Smith A, Lehmann L, Champlin R, Gillio A, Bajwa R, D'Agostino RB Sr, Massaro J, Warren D, Miloslavsky M, Hume RL, Iacobelli M, Nejadnik B, Hannah AL, Soiffer RJ.

Blood. 2016 Mar 31;127(13):1656-65. doi: 10.1182/blood-2015-10-676924. Epub 2016 Jan 29.

18.

Arterio-venous differences in cord levels of catecholamines, glucose, lactate and blood gases.

Koh DK, Hume R, Eisenhofer G, Watson J, Williams FL.

J Perinat Med. 2016 Aug 1;44(6):695-704. doi: 10.1515/jpm-2015-0323.

PMID:
26756086
19.

Cardiac remodelling during pregnancy: whither the guinea pig?

Taggart MJ, Hume R, Lartey J, Johnson M, Tong WC, Macleod KT.

Cardiovasc Res. 2014 Oct 1;104(1):226-7. doi: 10.1093/cvr/cvu198. Epub 2014 Aug 25. No abstract available.

20.

Maternal and fetal factors which influence cord blood glucose levels in term infants delivered by cesarean section.

Koh D, Hume R, Eisenhofer G, Ogston S, Watson J, Williams F.

J Perinat Med. 2015 May;43(3):339-46. doi: 10.1515/jpm-2014-0067.

PMID:
24914709
21.

Engineering mammary gland in vitro models for cancer diagnostics and therapy.

Campbell JJ, Hume RD, Watson CJ.

Mol Pharm. 2014 Jul 7;11(7):1971-81. doi: 10.1021/mp500121c. Epub 2014 Apr 25. Review.

PMID:
24766393
22.

A summary of the iodine supplementation study protocol (I2S2): a UK multicentre randomised controlled trial in preterm infants.

Williams F, Hume R, Ogston S, Brocklehurst P, Morgan K, Juszczak E; I2S2 team.

Neonatology. 2014;105(4):282-9. doi: 10.1159/000358247. Epub 2014 Feb 27.

PMID:
24576827
23.

Sodium and potassium currents influence Wallerian degeneration of injured Drosophila axons.

Mishra B, Carson R, Hume RI, Collins CA.

J Neurosci. 2013 Nov 27;33(48):18728-39. doi: 10.1523/JNEUROSCI.1007-13.2013.

24.

Potent and long-lasting inhibition of human P2X2 receptors by copper.

Punthambaker S, Hume RI.

Neuropharmacology. 2014 Feb;77:167-76. doi: 10.1016/j.neuropharm.2013.09.001. Epub 2013 Sep 22.

25.

Maternal and umbilical cord levels of T4, FT4, TSH, TPOAb, and TgAb in term infants and neurodevelopmental outcome at 5.5 years.

Williams FL, Watson J, Ogston SA, Visser TJ, Hume R, Willatts P.

J Clin Endocrinol Metab. 2013 Feb;98(2):829-38. doi: 10.1210/jc.2012-3572. Epub 2013 Jan 15.

PMID:
23322817
26.

The Highwire ubiquitin ligase promotes axonal degeneration by tuning levels of Nmnat protein.

Xiong X, Hao Y, Sun K, Li J, Li X, Mishra B, Soppina P, Wu C, Hume RI, Collins CA.

PLoS Biol. 2012;10(12):e1001440. doi: 10.1371/journal.pbio.1001440. Epub 2012 Dec 4.

27.
28.

High potency zinc modulation of human P2X2 receptors and low potency zinc modulation of rat P2X2 receptors share a common molecular mechanism.

Punthambaker S, Blum JA, Hume RI.

J Biol Chem. 2012 Jun 22;287(26):22099-111. doi: 10.1074/jbc.M112.369157. Epub 2012 May 3.

29.

A role for the calmodulin kinase II-related anchoring protein (αkap) in maintaining the stability of nicotinic acetylcholine receptors.

Mouslim C, Aittaleb M, Hume RI, Akaaboune M.

J Neurosci. 2012 Apr 11;32(15):5177-85. doi: 10.1523/JNEUROSCI.6477-11.2012.

30.

Mild maternal thyroid dysfunction at delivery of infants born ≤34 weeks and neurodevelopmental outcome at 5.5 years.

Williams F, Watson J, Ogston S, Hume R, Willatts P, Visser T; Scottish Preterm Thyroid Group.

J Clin Endocrinol Metab. 2012 Jun;97(6):1977-85. doi: 10.1210/jc.2011-2451. Epub 2012 Apr 4.

PMID:
22492778
31.

TRPM7 is required within zebrafish sensory neurons for the activation of touch-evoked escape behaviors.

Low SE, Amburgey K, Horstick E, Linsley J, Sprague SM, Cui WW, Zhou W, Hirata H, Saint-Amant L, Hume RI, Kuwada JY.

J Neurosci. 2011 Aug 10;31(32):11633-44. doi: 10.1523/JNEUROSCI.4950-10.2011.

32.

The measurement, definition, aetiology and clinical consequences of neonatal transient hypothyroxinaemia.

Williams F, Hume R.

Ann Clin Biochem. 2011 Jan;48(Pt 1):7-22. doi: 10.1258/acb.2010.010174. Epub 2010 Oct 7. Review.

PMID:
20930033
33.

Levels of neonatal thyroid hormone in preterm infants and neurodevelopmental outcome at 5 1/2 years: millennium cohort study.

Delahunty C, Falconer S, Hume R, Jackson L, Midgley P, Mirfield M, Ogston S, Perra O, Simpson J, Watson J, Willatts P, Williams F; Scottish Preterm Thyroid Group.

J Clin Endocrinol Metab. 2010 Nov;95(11):4898-908. doi: 10.1210/jc.2010-0743. Epub 2010 Aug 18.

PMID:
20719832
34.

touché Is required for touch-evoked generator potentials within vertebrate sensory neurons.

Low SE, Ryan J, Sprague SM, Hirata H, Cui WW, Zhou W, Hume RI, Kuwada JY, Saint-Amant L.

J Neurosci. 2010 Jul 14;30(28):9359-67. doi: 10.1523/JNEUROSCI.1639-10.2010.

35.

Na(v)1.6a is required for normal activation of motor circuits normally excited by tactile stimulation.

Low SE, Zhou W, Choong I, Saint-Amant L, Sprague SM, Hirata H, Cui WW, Hume RI, Kuwada JY.

Dev Neurobiol. 2010 Jun;70(7):508-22. doi: 10.1002/dneu.20791.

36.
37.

Perinatal factors affecting thyroid hormone status in extreme preterm infants.

Williams FL, Hume R.

Semin Perinatol. 2008 Dec;32(6):398-402. doi: 10.1053/j.semperi.2008.09.004. Review.

PMID:
19007676
38.

Opposite effects of zinc on human and rat P2X2 receptors.

Tittle RK, Hume RI.

J Neurosci. 2008 Oct 29;28(44):11131-40. doi: 10.1523/JNEUROSCI.2763-08.2008.

39.

Amino acid variations resulting in functional and nonfunctional zebrafish P2X(1) and P2X (5.1) receptors.

Low SE, Kuwada JY, Hume RI.

Purinergic Signal. 2008 Dec;4(4):383-92. doi: 10.1007/s11302-008-9124-0. Epub 2008 Oct 11.

40.

Hepatic and adipose tissue depot-specific changes in lipid metabolism in Late-onset Obese (LOB) rats.

Frick F, Hume R, Robinson IC, Edén S, Oscarsson J.

Lipids. 2008 Apr;43(4):313-24. doi: 10.1007/s11745-008-3164-7. Epub 2008 Mar 12.

PMID:
18335266
41.

Contribution of extracellular negatively charged residues to ATP action and zinc modulation of rat P2X2 receptors.

Friday SC, Hume RI.

J Neurochem. 2008 May;105(4):1264-75. doi: 10.1111/j.1471-4159.2008.05228.x. Epub 2008 Jan 14.

42.

The zebrafish ennui behavioral mutation disrupts acetylcholine receptor localization and motor axon stability.

Saint-Amant L, Sprague SM, Hirata H, Li Q, Cui WW, Zhou W, Poudou O, Hume RI, Kuwada JY.

Dev Neurobiol. 2008 Jan;68(1):45-61.

43.
44.

A histidine scan to probe the flexibility of the rat P2X2 receptor zinc-binding site.

Tittle RK, Power JM, Hume RI.

J Biol Chem. 2007 Jul 6;282(27):19526-33. Epub 2007 May 21.

45.

Genetic variation in hepatic glucose-6-phosphatase system genes in cases of sudden infant death syndrome.

Forsyth L, Scott HM, Howatson A, Busuttil A, Hume R, Burchell A.

J Pathol. 2007 May;212(1):112-20.

PMID:
17354259
46.

Transient hypothyroxinaemia in preterm infants.

Williams FL, Visser TJ, Hume R.

Early Hum Dev. 2006 Dec;82(12):797-802. Epub 2006 Oct 31. Review.

PMID:
17079099
47.

Effect of the ABO blood group on the proliferative and clonogenic capacity of umbilical cord stem cells.

Galan I, Santolaya-Forgas J, Leon JD, Uhlmann RA, Montenegro D, Hume R, Mari G.

Transfus Apher Sci. 2006 Oct;35(2):119-23. Epub 2006 Oct 11.

PMID:
17045528
48.

Alcohol abuse--a persistent preventable risk for congenital anomalies.

Baumann P, Schild C, Hume RF, Sokol RJ.

Int J Gynaecol Obstet. 2006 Oct;95(1):66-72. Epub 2006 Aug 22.

PMID:
16926014
49.

Fetal growth curves for an ethnically diverse military population: the American Institute of Ultrasound in Medicine-accredited platform experience.

Elliott D, Patience T, Boyd E, Hume RF Jr, Calhoun BC, Napolitano PG, Apodaca CC.

Mil Med. 2006 Jun;171(6):508-11.

PMID:
16808131
50.

The effect of agrin and laminin on acetylcholine receptor dynamics in vitro.

Bruneau EG, Macpherson PC, Goldman D, Hume RI, Akaaboune M.

Dev Biol. 2005 Dec 1;288(1):248-58. Epub 2005 Oct 26.

Supplemental Content

Support Center